ArticleEye (London, England)2022
Assessment of serum catalase, reduced glutathione, and superoxide dismutase activities and malondialdehyde levels in keratoconus patients.
Article in Eye (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- THE PROTECTIVE ROLE OF FLAVONOIDS IN AMNESIA -SYSTEMATIC REVIEW.F1000Research · 2025Pooled it
- Update on the Physiopathology of Keratoconus.Medical sciences (Basel, Switzerland) · 2026Review
- Electroacupuncture alleviates depressive symptoms in post-stroke depression rat models by AMPK-mediated mitochondrial pathway.Psychopharmacology · 2026Article
- Therapeutic Efficacy of Carvacrol-Loaded Mesoporous Silicate Nanoparticles Against Cryptosporidiosis.Pharmaceutics · 2026Article
- Syringic acid pretreatment potentiates antioxidant mechanism and downregulates inflammatory signaling towards doxorubicin-related oxidoinflammatory hepatorenal damage in rats.Scientific reports · 2026Article
- Imbalance of Pro-Oxidant and Anti-Oxidant Biomarkers in Patients with Keratoconus.Antioxidants (Basel, Switzerland) · 2026Article
- Modulation of PDX1 gene expression and glycemic control by Citrullus lanatus in experimental type 2 diabetes.Scientific reports · 2026Article
- Article
- Exploring biomarkers for keratoconus: current insights and future directions.Molecular biology reports · 2025Review
- Investigating prolactin-induced protein and its role in modulating the metabolic state of the keratoconus microenvironment.Experimental eye research · 2025Review
- Keratoconus: The Local Manifestation of a Systemic Disease?Journal of clinical medicine · 2025Review
- Comparative Analysis of Oxidative Stress Biomarkers in 50 Primary Open-Angle Glaucoma Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Cardiovascular Toxicity of Metal-Based Nanoparticles.International journal of molecular sciences · 2025Review
- Tear Proteomic Analysis From Offspring of Keratoconus Patients: New Insights Into Corneal Biomechanical Weakness and Disease Risk Stages.Investigative ophthalmology & visual science · 2025Article
- Design, Synthesis, and Molecular Docking of Quinazolines Bearing Caffeoyl Moiety for Targeting of PGK1/PKM2/STAT3 Signaling Pathway in the Human Breast Cancer.Current pharmaceutical design · 2025Article
- Comparison of Glutathione Nanoparticles, CoEnzyme Q10, and Fish Oil for Prevention of Oxygen-Induced Retinopathy in Neonatal Rats.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Systemic and Ocular Associations of Keratoconus.Expert review of ophthalmology · 2024Article
- Oxidative Stress in the Anterior Ocular Diseases: Diagnostic and Treatment.Biomedicines · 2023Review
- GC-MS chemical profiling, antioxidant, anti-diabetic, and anti-inflammatory activities of ethyl acetate fraction ofFrontiers in pharmacology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate the relationship between keratoconus disease and the antioxidant activities of catalase (CAT), reduced glutathione (GSH) and superoxide dismutase (SOD) and the level of the oxidative stress marker malondialdehyde (MDA) in serum.
methodsThe study included 50 patients diagnosed with keratoconus and 53 healthy age- and sex-matched control subjects. The keratoconus patients were grouped according to the four keratoconus stages based on the modified Krumeich keratoconus classification system. The CAT, GSH and SOD activities and MDA levels in the serum samples collected from the patient and control groups were compared.
resultsThe mean serum CAT, GSH, SOD and MDA levels in the keratoconus group were determined to be 0.075 (0.074-0.078)U/L, 0.002 (0.001-0.006) mmol/ml, 1.56 (1.51-1.62)U/L and 1.69 (1.65-1.99) mmol/L, respectively, and those in the control group were determined to be 0.024 (0.013-0.037)U/L, 0.029 (0.018-0.049) mmol/ml, 4.13 (4.01-4.17) U/L and 0.74 (0.65-0.82) mmol/L. The serum GSH levels and SOD activity were significantly lower in the keratoconus group (p < 0.001 for both) than in the control group while the CAT activity and MDA levels were significantly higher (p < 0.001 for both).
conclusionThe low serum GSH levels and SOD activity and the high CAT activity and MDA levels observed in this study suggest the presence of oxidative stress and inadequate antioxidant defence mechanisms in keratoconus patients. The studied parameters may offer auxiliary markers for use in the diagnosis and treatment of the keratoconus disease and in its potential therapeutic targets in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.